---
title: "Valion Bio Reports Q1 Results, Advances Entolimod Platform"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286477206.md"
description: "Valion Bio (VBIO) reported its Q1 2026 results, marking its first full reporting period post-divestiture of its consumer bioelectronics business. The company advanced its Entolimod platform for medical countermeasures and oncology support, while operating expenses rose to $5.6 million, leading to a net loss of $6.2 million. Valion has $7.2 million in cash and is exploring capital-raising options. Spark's analysis rates VBIO as Neutral due to weak financial performance and mixed technicals. Valion Bio focuses on immunotherapeutics, with its lead candidate, Entolimod, receiving Fast Track and Orphan Drug designations."
datetime: "2026-05-14T22:33:28.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286477206.md)
  - [en](https://longbridge.com/en/news/286477206.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286477206.md)
---

# Valion Bio Reports Q1 Results, Advances Entolimod Platform

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Valion Bio ( (VBIO) ) has provided an update.

On May 14, 2026, Valion Bio reported its first-quarter 2026 results, marking its first full reporting period under the new corporate identity and post-divestiture of its legacy consumer bioelectronics business. During the quarter ended March 31, 2026, the company advanced its Entolimod platform toward potential use as a medical countermeasure and oncology supportive care therapy, broadened engagement with U.S. government agencies, and deepened integration of Velocity Bioworks as both an internal manufacturing engine and an emerging third-party CDMO revenue source.

Management highlighted that Entolimod’s differentiated profile and domestic manufacturing footprint are aligning it with national stockpile modernization and allied preparedness priorities, while next-generation TLR5 agonist Entolasta progressed as a platform extension into longevity and immunosenescence. Operating expenses rose to $5.6 million from $1.4 million a year earlier, driving a wider net loss of $6.2 million, as Valion absorbed Velocity Bioworks costs, invested in regulatory and development programs, and incurred one-time rebranding and listing-change expenses, leaving cash of $7.2 million at quarter-end and prompting ongoing evaluation of capital-raising options.

**Spark’s Take on VBIO Stock**

According to Spark, TipRanks’ AI Analyst, VBIO is a Neutral.

The score is primarily constrained by very weak financial performance (shrinking revenue, persistent losses, negative cash flow, and significant balance-sheet erosion). Technicals are mixed but generally pressured by longer-term downtrends, while valuation is hard to support due to negative earnings and no dividend data.

To see Spark’s full report on VBIO stock, click here.

**More about Valion Bio**

Valion Bio, Inc., formerly Tivic Health Systems, Inc., is a clinical-stage immunotherapeutics company developing biologic drugs that activate innate immune pathways for cytoprotection and immune modulation in conditions driven by radiation, disease and immune dysregulation. Its lead candidate, Entolimod, a Toll-like receptor 5 agonist for acute radiation syndrome, is supported by Fast Track and Orphan Drug designations, while its in-house CDMO arm, Velocity Bioworks in San Antonio, targets a structurally underserved U.S. Phase I and II biologics manufacturing market.

**Average Trading Volume:** 307,483

**Technical Sentiment Signal:** Sell

**Current Market Cap:** $3.45M

Learn more about VBIO stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [VBIO.US](https://longbridge.com/en/quote/VBIO.US.md)

## Related News & Research

- [MBX Biosciences Highlights Sustained Calcium Control In Rare Disease](https://longbridge.com/en/news/289614050.md)
- [10:33 ETConsano Bio to Present Clinical Development of C-1101 for Chronic Sciatica at 2026 BIO International Convention](https://longbridge.com/en/news/289344273.md)
- [Lipocine Advances LPCN 1154 for Postpartum Depression](https://longbridge.com/en/news/289641823.md)
- [12:38 ETAlbert Einstein College of Medicine Launches BIO-VITAL to Accelerate  Gerotherapeutics](https://longbridge.com/en/news/289219051.md)
- [21:15 ETPeer-reviewed Publication Shows that Lateral Pharma's SCP Drugs for Neuropathic Pain Act Via the Novel Target LanCL1](https://longbridge.com/en/news/289530740.md)